Editas Medicine (EDIT) Tops Q1 EPS by 5c

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.74), $0.05 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $3.85 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• Strong US consumer demand lifts P&G annual profit forecast
• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing